Calcium acetate - Fresenius Medical Care

Drug Profile

Calcium acetate - Fresenius Medical Care

Alternative Names: PhosLo Gelcaps; PhosLo Tablets; Phoslyra; Phosphosorb

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Braintree Laboratories
  • Developer Fresenius Medical Care
  • Class Acetates; Calcium supplements; Electrolytes; Small molecules
  • Mechanism of Action Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperphosphataemia

Most Recent Events

  • 06 Jun 2012 The US FDA approves ANDA for calcium acetate capsules for Hyperphosphataemia in USA (PO)
  • 16 Aug 2011 Launched for Hyperphosphataemia in USA (PO, liquid)
  • 26 Jun 2009 Launched for Hyperphosphataemia in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top